Document text
Principal Investigator: Xiaobo Zhou
Organization: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
Fiscal Year: 2024
Award: $351,000
Funding agency: National Library of Medicine
The COVID-19 pandemic has presented new challenges to individuals world-wide. Since the first reports of
infections in the US more than 90 million individuals have become infected and more than 1 million have died.
SARS-CoV-2 genome has various open reading frames (ORFs) encoding 16 non-structural proteins (NSPs), 4
structural proteins and several accessory proteins. The genome of RNA virus can easily generate mutations as
virus spreads. The constant emergence of new mutations in SARS-CoV-2 is the major challenge for the ongoing
development of antiviral drug and broad neutralizing antibodies. The two mRNA vaccines from Pfizer/BioNTech
and Moderna are moderate effective, 45 to 75 percent at protecting people from in preventing infection from the
delta variant, and both of them have received emergency use authorization. More seriously, the omicron variant
was first detected in southern Africa and quickly expanded to the whole world. According to a recent study,
traditional dosing regimens of COVID-19 vaccines available in the US do not produce antibodies capable of
recognizing and neutralizing the Omicron variant. The global data shows the coronavirus pandemic is far from
over. Thus, more variants are expectable and some of them may escape the immune response produced after
vaccination. How to keep the efficacy of existing mRNA vaccines on variants is challenging us. Aside from SARS-
CoV-2, mRNA medicines against cancer and other infectious disease, such as Ebola, Zika virus, and influenza,
are advancing through clinical trials.
The goal of this project is to develop an integrated deep learning model to optimize 5'UTR, codon usage, and
3'UTR at same time that enables users to design the optimal mRNA sequence to enhance protein expression
level, thus to improve the efficacy of mRNA medicines. mRNA medicines hold great promise for the treatment of
a wide variety of disease, extending from prophylactics to therapeutics for infectious diseases, cancer, and
genetic disease. mRNA medicines have several beneficial features: safety, efficacy, production, and speed.
Multiple factors are involved to regulate the stability and efficiency of mRNA, including 5' untranslated region
(UTR), 3' UTR, codon et al, and several in silico approaches have being developed to optimize these factors
respectively However, as these factors always function together during the translation of mRNA, and individual
optimization is insufficient. Thus, a novel integrated deep learning model for these factors is needed to
comprehensively enhance the stability and efficiency of mRNA medicine. In silico optimization of mRNA vaccine
provides a fast methodology to investigate all possible integration of the ORF, 5' UTR and 3'UTR and identify
the optimal mRNA vaccine. The interdisciplinary team proposed to develop the following aims: (1) developing
deep learning models for 5' UTR, codon, and 3' UTR respectively, and integrated model for systemic optimization
of 5' UTR, codon, and 3' UTR; and (2) experimentally validate the integrated models by designing the 5'UTR,
codon, and 3'UTR sequence for representative.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><3' Untranslated Regions><3'UTR><5' Untranslated Regions><5'UTR><Affect><Antibodies><Antibody titer measurement><Antigen Targeting><Antigens><Atlases><B.1.1.529><B.1.617.2><BNT 162b2><BNT162b2><Biology><Body Tissues><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 genome><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus genome><COVID-19 years><COVID19 genome><COVID19 virus><COVID19 virus genome><CV-19><Cancers><Cell Body><Cells><Clinical Trials><CoV pandemic><CoV-2><CoV2><Codon><Codon Nucleotides><Communicable Diseases><Coronavirus Infectious Disease 2019><Data><Data Set><Delta variant><Dendritic Cells><Development><Disease><Disorder><Dose><Ebola><Encapsulated><Equilibrium><FDA EUA><FDA Emergency Use Authorization><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Future><GTEx><Genes><Genetic Alteration><Genetic Change><Genetic Diseases><Genetic defect><Genome><Genotype-Tissue Expression Project><Globin><Goals><Grippe><Half-Life><Hemoglobin><Human><Immune><Immune response><Immunes><Immunological response><In Vitro><Individual><Infection><Infection prevention><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Malignant Neoplasms><Malignant Tumor><Medicine><Messenger RNA><Methodology><Micro RNA><MicroRNAs><Modeling><Modern Man><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Mutation><Non-structural Protein><Nonstructural Protein><ORFs><Omicron variant><Open Reading Frames><Persons><Pfizer covid19 vaccine><Pfizer-BioNTech COVID-19 vaccine><Pfizer-BioNTech coronavirus disease 2019 vaccine><Pfizer/BioNTech vaccine><Play><Poly(A) Tail><Prevent infection><Production><Protein Coding Region><Proteins><Proteomics><RNA Viruses><RNA vaccine><RNA-based vaccine><Regimen><Reporting><Resistance><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.1.529><SARS-CoV-2 B.1.617.2><SARS-CoV-2 delta><SARS-CoV-2 epidemic><SARS-CoV-2 genome><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 omicron><SARS-CoV-2 omicron variant><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 genome><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Southern Africa><Speed><Spikevax><Structural Protein><Structure><Techniques><Testing><Therapeutic><Time><Tissues><Translating><Translations><UTRs><United States><Untranslated Regions><Vaccinated><Vaccination><Vaccines><Variant><Variation><Veiled Cells><Virus><Wuhan coronavirus><ZIKV><Zika Virus><access to vaccination><access to vaccines><anti-viral development><anti-viral drug development><anti-viral therapeutic development><anti-viral therapy development><antibody titering><antiviral development><antiviral drug development><antiviral therapeutic development><antiviral therapy development><balance><balance function><booster dose><booster shot><booster vaccine><cell type><conventional dosage><conventional dosing><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 genome><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease 2019 virus genome><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus pandemic><cost effective><deep learning><deep learning based model><deep learning based neural network><deep learning method><deep learning model><deep learning neural network><deep learning strategy><deep neural net><deep neural network><design><designing><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><developmental><emergency use authorization><genetic condition><genetic disorder><genome mutation><hCoV19><host response><immune system response><immunogen><immunoresponse><improved><in silico><in vivo><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA Leader Sequences><mRNA Stability><mRNA Translation><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><malignancy><manufacture><miRNA><miRNAs><model design><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><neoplasm/cancer><neutralizing antibody><novel><omicron variant of COVID-19><omicron variant of SARS-CoV-2><p-Globin><prophylactic><protein expression><resistant><severe acute respiratory syndrome coronavirus 2 B.1.1.529><severe acute respiratory syndrome coronavirus 2 B.1.617.2><severe acute respiratory syndrome coronavirus 2 genome><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><social role><traditional dosage><traditional dosing><translation><vaccination access><vaccination availability><vaccine access><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine availability><vaccine boost><vaccine candidates against SARS-CoV-2><vaccine effectiveness><vaccine for novel coronavirus><vaccine platform><vaccines preventing COVID><vaccines to prevent COVID><zikav>